07X.F ANNOVIS BIO INC. DL-0001
- Market cap
- EUR 33.0M
- P/E
- -
- P/B
- 24.00x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 07X.F undervalued?
Graham numberThe Graham number of ANNOVIS BIO INC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ANNOVIS BIO INC. DL-0001 fundamental analysis
No fundamental analysis for ANNOVIS BIO INC. DL-0001 yet.
ANNOVIS BIO INC. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ANNOVIS BIO INC. DL-0001
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to …
Full company profileANNOVIS BIO INC. DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ANNOVIS BIO INC. DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -14.5M | -25.5M | -45.0M | -26.7M | -29.7M | -64.8M |
| EBITDA | - | -25.5M | -45.0M | -26.7M | -29.7M | -64.8M |
| Net Income | -14.5M | -25.3M | -56.2M | -24.6M | -28.9M | -64.9M |
| EPS | -1.79 | -3.10 | -5.34 | -1.74 | -1.06 | -1.52 |
| Balance Sheet | ||||||
| Total Assets | 46.0M | 36.0M | 10.2M | 13.9M | 21.1M | 22.0M |
| Total Liabilities | 1.51M | 7.70M | 18.0M | 4.62M | 4.23M | 26.3M |
| Shareholders' Equity | 44.5M | 28.3M | -7.75M | 9.31M | 16.9M | -4.25M |
| Cash & Short-term Investments | 45.7M | 28.4M | 5.75M | 10.6M | 19.5M | 18.7M |
| Cash Flow | ||||||
| Operating Cash Flow | -9.13M | -17.3M | -40.0M | -21.9M | -25.6M | -61.9M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -9.13M | -17.3M | -40.0M | -21.9M | -25.6M | -61.9M |
| Ratios | ||||||
| ROE | -32.6% | -89.4% | - | -264.2% | -171.2% | - |
| ROA | -31.5% | -70.3% | -550.6% | -176.6% | -136.9% | -294.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ANNOVIS BIO INC. DL-0001 dividends
ANNOVIS BIO INC. DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns ANNOVIS BIO INC. DL-0001
- Insiders 16.17%
- Institutions 15.51%
- Public & others 68.32%
- Shares outstanding 43.0M
- Free float 35.9M
ANNOVIS BIO INC. DL-0001 company profile
- Company name
- ANNOVIS BIO INC. DL-0001
- Ticker
- 07X.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 101 Lindenwood Drive, Malvern, PA, United States, 19355
- Phone
- 484 875 3192
- Website
- annovisbio.com
About ANNOVIS BIO INC. DL-0001
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
ANNOVIS BIO INC. DL-0001 management
5- Dr. Maria L. Maccecchini Ph.D.Founder, Acting CFO, CEO, President & Executive Director · born 1951
- Dr. Cheng Fang Ph.D.Chief Scientific Officer
- Ms. Eve M. Damiano M.S., RACSenior Vice President of Regulatory Operations
- Mr. Blake Jensen M.B.A.Head of Quality
- Ms. Hilda MaibachSenior Vice President of Statistics